Title:
USE OF HADES AS A NEGATIVE MODULATOR OF AKT
Document Type and Number:
WIPO Patent Application WO/2012/134234
Kind Code:
A2
Abstract:
The present invention relates to the use of Hades as a negative modulator of Akt, and more particularly, to a negative modulator of Akt (protein kinase B) or anticancer agent containing, as an active ingredient, the Hades protein or a gene that encodes Hades protein. Akt, which is a serine/threonine-specific protein kinase, functions in a variety of cell processes including cell proliferation, cell survival, and tumor development. The inventors of the present invention have identified Hades as being a negative modulator of Akt and having a RING finger domain and E3 ubiquitin ligase activity. According to the present invention, Akt may directly interact with Hades, and may be ubiquitinated by Hades in vitro and in vivo. Therefore, the Hades of the present invention may decompose Akt and negatively modulate the downstream signaling thereof to inhibit the proliferation and survival of cancer cells, and therefore may be effectively used as an anticancer agent.
More Like This:
Inventors:
AN SUNG KWAN (KR)
BAE SEUNG HEE (KR)
BAE SEUNG HEE (KR)
Application Number:
PCT/KR2012/002408
Publication Date:
October 04, 2012
Filing Date:
March 30, 2012
Export Citation:
Assignee:
UNIV KONKUK IND COOP CORP (KR)
AN SUNG KWAN (KR)
BAE SEUNG HEE (KR)
AN SUNG KWAN (KR)
BAE SEUNG HEE (KR)
International Classes:
A61K31/7088; A61K31/7105; A61K38/08; A61K38/10; A61K48/00; A61P35/00
Domestic Patent References:
| WO2005056594A1 | 2005-06-23 |
Foreign References:
| US20080131526A1 | 2008-06-05 | |||
| KR20060066714A | 2006-06-16 |
Other References:
JUNG, JIN HYUK: 'Hades is a Novel p53-interacting and-ubiquitinating Protein That Negatively Regulates the Exonuclear Function ofp53' KONKUK GRADUATE SCHOOL, DOCTOR'S THESIS June 2010, pages 1 - 99
Attorney, Agent or Firm:
LEE, Moon-Sup (1659-2 Inhundong Gwanak-gu, Seoul 151-832, KR)
Download PDF:
Claims: